The estimated Net Worth of Eric D. Shaff is at least $2.19 Milione dollars as of 15 August 2024. Mr. Shaff owns over 7,813 units of Seres Therapeutics Inc stock worth over $155,937 and over the last 9 years he sold MCRB stock worth over $0. In addition, he makes $2,032,550 as President, Chief Executive Officer e Director at Seres Therapeutics Inc.
Eric has made over 10 trades of the Seres Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 7,813 units of MCRB stock worth $8,204 on 15 August 2024.
The largest trade he's ever made was exercising 31,250 units of Seres Therapeutics Inc stock on 14 February 2024 worth over $32,813. On average, Eric trades about 5,165 units every 128 days since 2015. As of 15 August 2024 he still owns at least 148,511 units of Seres Therapeutics Inc stock.
You can see the complete history of Mr. Shaff stock trades at the bottom of the page.
Eric D. Shaff serves as President, Chief Executive Officer, Director of the Company. Previously, he served as our Chief Operating and Financial Officer and Executive Vice President from January 2018 until January 2019 and as our Chief Financial Officer from November 2014 until January 2019. Mr. Shaff has also served on the board of directors of Sigilon Therapeutics, Inc. since November 2017. From January 2012 to November 2014, Mr. Shaff was Vice President of Corporate Finance for Momenta Pharmaceuticals (“Momenta”), a biotechnology company, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. From June 2004 to December 2011, Mr. Shaff held a number of corporate development and finance positions with Genzyme Corporation, a biotechnology company, most recently as Vice President of Finance/Controller for the Personalized Genetic Health division. Mr. Shaff received his B.A. from the University of Pennsylvania and his M.B.A. from Cornell University.
As the President, Chief Executive Officer e Director of Seres Therapeutics Inc, the total compensation of Eric Shaff at Seres Therapeutics Inc is $2,032,550. There are no executives at Seres Therapeutics Inc getting paid more.
Eric Shaff is 44, he's been the President, Chief Executive Officer e Director of Seres Therapeutics Inc since 2019. There are 20 older and no younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
Eric's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... e Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: